Momenta Pharmaceuticals Initiates Phase I Clinical Study for M118 Subcutaneous Formulation

Momenta Pharmaceuticals, Inc. has initiated a Phase I study of a subcutaneous formulation of M118, its lead novel development candidate.

The study will evaluate the human safety, tolerability, bioavailability and pharmacokinetics of the compound.

M118 is a next-generation anticoagulant designed specifically for use in treating patients diagnosed with acute coronary syndromes (ACS).

M118 administered intravenously demonstrates superior efficacy to a standard dose of unfractionated heparin (UFH) in a preclinical model of acute arterial thrombosis.

This increase in efficacy did not result in an increased risk of bleeding.

It is anticipated that an important feature of M118 will be its flexibility in being formulated for both intravenous and subcutaneous administration to be most appropriate for individual ACS patients.

Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals, Inc.
Supergenerics

Downloads

DownloadFull Press Release